Attorneys at McDermott Will & Schulte LLP have compiled the latest 340B litigation updates covering the week of June 30 through July 6, 2026.
The weekly roundup draws on a review of dockets from more than 50 active 340B cases to deliver timely summaries of developments in this closely watched area of healthcare law.
Issues at stake across the tracked cases this week span contract pharmacy arrangements, a rebate model pilot programme, and several other contested matters.
In a qui tam action arguing that private parties can bring suits to enforce the 340B Statute, defendants filed a renewed motion to dismiss the plaintiff’s first amended complaint.
Two individual defendants in that same qui tam case also filed supplemental memorandums in support of the defendants’ renewed motion to dismiss, adding further legal weight to their challenge.
In three consolidated cases brought by a trade association and drug manufacturers challenging a Louisiana state law governing contract pharmacy arrangements, the court entered its judgment.
The Louisiana ruling represents a significant development in ongoing efforts by manufacturers and industry groups to push back against state-level 340B access requirements.
In a separate appealed case challenging the 340B Rebate Model Pilot Program, the appellants filed a reply brief, keeping that dispute active at the appellate level.
A covered entity also filed a complaint against a drug manufacturer, alleging that the covered entity is being denied access to 340B pricing due to data reporting requirements imposed by the manufacturer.
The complaint highlights continued tensions between covered entities and manufacturers over the conditions under which 340B discounts must be made available.
In another appealed case, this one challenging a district court’s denial of a drug manufacturer’s motion for a preliminary injunction, the court of appeals affirmed the district court’s ruling.
That affirmation is a setback for the manufacturer involved and signals continued judicial reluctance to grant preliminary injunctive relief in these types of 340B disputes.
The 340B Drug Pricing Program governs the sale of outpatient drugs at significantly reduced prices to eligible hospitals and healthcare providers serving low-income populations.
McDermott Will & Schulte LLP publishes this weekly tracker to help healthcare industry participants follow how 340B litigation is evolving across federal courts throughout the United States.